EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension

Summary

This was a multicenter, open-label study to evaluate the dose of Orenitram® (treprostinil) Extended Release Tablets achieved at 16 weeks after a short-term course of Remodulin® (treprostinil) Injection in subjects with pulmonary arterial hypertension (PAH).

Timeline

Start

2019-01-31

Primary completion

2022-05-11

Completion

2022-05-11

Outcome

Met primary endpoint

paper At Week 16, the mean daily oral treprostinil dose was 16.4 mg; 79% of patients met the primary endpoint. PMID 37532157 ↗

Publications

• Miller CE, Franco V, Smith JS, Balasubramanian V, Kingrey J, Zolty R, Melendres-Groves L, Huston J, Elwing JM, Ravichandran A, Cella D, Shen E, Seaman S, Thrasher CM, Broderick M, Oudiz RJ. Parenteral treprostinil induction for rapid attainment of therapeutic doses of oral treprostinil. Respir Med. 2023 Nov;218:107374. doi: 10.1016/j.rmed.2023.107374. Epub 2023 Aug 1.

Drugs

Indications